NeoGenomics will be exhibiting at the 2022 ASCO Annual Meeting from June 4 – 6, 2022. Divisions across NeoGenomics will be present at the booth, including Clinical Services, Informatics, Pharma Services and Inivata. Here is a sneak peek of what we have planned to share at our booth, #18103. We are looking forward to meeting you at the 2022 ASCO Annual Meeting.
The NeoGenomics clinical division is introducing ASCO attendees to NeoTYPE® DNA & RNA - Lung, a streamlined next-generation sequencing solution.
This test is targeted, focusing on the 50 genes most critical to NSCLC, plus TMB, MSI, and optional PD-L1. Its turnaround time is 14 days, and it can reflex to liquid biopsy if tissue is insufficient.
RNA NGS has advantages over DNA NGS for fusion detection, which is why NeoGenomics integrates DNA and RNA sequencing in one report to maximize actionable results. The report is curated to provide the right amount of information, including potential therapies and clinical trials. Fusions are becoming increasingly relevant in the rapidly developing field of precision medicine. For cases of advanced NSCLC, there are 4 FDA-approved therapies targeting ALK, ROS1, NTRK and RET fusions – and more are under investigation.
NeoGenomics is proud to be your One Lab. To learn more about NeoTYPE® DNA & RNA - Lung, we invite you to learn more.
RaDaRTM and the Find It with RaDaR™ augmented reality activity
Attendees will get a peek at RaDaR™, a personalized multi-tumor assay, that detects minimal residual disease (MRD) recurrence following curative intent therapy and has exceptional sensitivity with a simple blood draw. MRD tests work by detecting circulating tumor DNA, a biomarker indicating the presence of cancer in a patient’s blood.
We are excited to debut a brand new activity called Find It with RaDaR.™ It is an augmented reality experience where participants are educated about minimal residual disease (MRD) and detection of ctDNA in blood. The player’s real-world surroundings will be augmented so they can find and collect as many ctDNA fragments as possible in 48 seconds. RaDaR can accurately detect up to 48 tumor-specific variants. ASCO attendees who participate will also be supporting a good cause.
Each time an attendee plays, NeoGenomics will donate $25 toward Conquer Cancer®, the ASCO Foundation. Your participation during the 2022 ASCO Annual Meeting will help advance their vision of a world where cancer is prevented or cured and every survivor is healthy. Our goal is to raise $10,000 to support their mission of accelerating breakthroughs in lifesaving research and empower people everywhere to conquer cancer.
Follow us on social media, where we will be sharing updates on how much we raised.
NeoGenomics Informatics invites guests to experience our newest Informatics products – Cohort Builder and NeoPixel image bank. They enable users to create and visualize their own cohorts using real-time lab data from the largest volume oncology testing lab in the United States.
Attendees can also learn more about NeoGenomics’ full portfolio of services, including data licenses and tokenization, lab alerts and clinical trial matching.
To download the fact sheet and learn how Cohort Builder can accelerate your biomarker programs, oncology clinical trials and commercial launches, visit: Cohort Builder
Inivata is NeoGenomics’ liquid biopsy-focused subsidiary. Inivata will be presenting data that was produced with their collaborators about the potential of ctDNA detection via liquid biopsy in a range of indications, including lung cancer, head and neck cancer, melanoma and breast cancer.
Members from Inivata’s clinical, medical, and business development teams will be attending ASCO in person, and they are taking requests to schedule meetings. Visit them online to learn more.
Be sure to check out the touch-screen, interactive map where ASCO attendees can see and learn more about our Pharma facilities and services. NeoGenomics Pharma Services has international sites with expertise and a breadth of capabilities, which enable us to support global clinical trials.